Trelegy Ellipta vs Mounjaro
Side-by-side drug price comparison from Medicare Part D data
Verdict
Trelegy Ellipta costs 44% less per claim than Mounjaro ($380.00 vs $673.00). Neither drug has a generic alternative available. Total Medicare spending: Trelegy Ellipta at $2.9B vs Mounjaro at $2.5B.
| Metric | Trelegy Ellipta | Mounjaro |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $380* | $673 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $2.9B | $2.5B |
| Total Claims | 7,560,000 | 3,680,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 19.8%* | 312.4% |
| Generic Available | No | No |
| Condition | Asthma/COPD | Diabetes |
| Total Beneficiaries | 865,000 | 524,000 |
Trelegy Ellipta costs 44% less per claim than Mounjaro ($380.00 vs $673.00). Neither drug has a generic alternative available. Total Medicare spending: Trelegy Ellipta at $2.9B vs Mounjaro at $2.5B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Trelegy Ellipta and Mounjaro. What follows is the interpretation — which specific axes carry the most weight for Trelegy Ellipta versus Mounjaro, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.